DG Comp punishes Lundbeck over pay-for-delay

19 June 2013

DG Comp punishes Lundbeck over pay-for-delay Lundbeck says it was legitimately protecting its intellectual property

The European Commission has fined pharmaceutical company Lundbeck €94 million and several generic drug makers €52 million for delaying the entry of generic drugs to the EU market. It is the first fine issued in a reverse-payment case under European law.